FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995356102> ?p ?o ?g. }

• W1995356102 endingPage "1675" @default.
• W1995356102 startingPage "1667" @default.
• W1995356102 abstract "There is increasing evidence that tumor necrosis factor alpha (TNFalpha) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti-TNFalpha therapy with etanercept, a 75-kd receptor fusion protein, in active AS.This multicenter trial had 2 phases: an initial placebo-controlled period of 6 weeks' duration and an observational phase lasting 24 weeks. Thirty patients with active AS were included. They were randomized into 2 groups, which received either etanercept (25 mg twice weekly) (n = 14) or placebo (n = 16) for 6 weeks. Then both groups were treated with etanercept. Nonsteroidal antiinflammatory drug (NSAID) treatment could be continued, but disease-modifying antirheumatic drugs (DMARDs) and steroids had to be withdrawn prior to the study. All patients received etanercept for a total of 12 weeks and were followed up for at least 24 weeks. The Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index, Bath AS Metrology Index, pain level on a numeric rating scale, quality of life by the Short Form 36, and C-reactive protein (CRP) level were assessed. The primary outcome parameter was a >or=50% improvement in the BASDAI.Treatment with etanercept resulted in at least a 50% regression of disease activity in 57% of these patients at week 6, versus 6% of the placebo-treated patients (P = 0.004). After the placebo-treated patients switched to etanercept, 56% improved. The mean +/- SD BASDAI improved from 6.5 +/- 1.2 at baseline to 3.5 +/- 1.9 at week 6 in the etanercept group, with no improvement in the placebo group (P = 0.003 between groups). Similarly, pain, function, mobility, and quality of life improved with etanercept but not with placebo at week 6 (P < 0.05). Mean CRP levels decreased significantly with etanercept but not with placebo (P = 0.001). There was ongoing improvement in all parameters in both groups until week 12 and week 18, respectively (i.e., throughout the period of etanercept treatment). Disease relapses occurred a mean +/- SD of 6.2 +/- 3.0 weeks after cessation of etanercept. No severe adverse events, including major infections, were observed during the trial.This study shows that on a short-term basis (3 months), treatment with etanercept is clearly efficacious in patients with active AS who are receiving NSAID therapy but not DMARDs or steroids. After cessation of therapy, almost all patients experienced a relapse within a few weeks. Thus, it seems probable that etanercept must be administered continuously in most AS patients to achieve permanent inhibition of the inflammatory process." @default.
• W1995356102 created "2016-06-24" @default.
• W1995356102 creator A5010256118 @default.
• W1995356102 creator A5010659953 @default.
• W1995356102 creator A5011554462 @default.
• W1995356102 creator A5020029860 @default.
• W1995356102 creator A5035158215 @default.
• W1995356102 creator A5044290696 @default.
• W1995356102 creator A5069831361 @default.
• W1995356102 creator A5081920237 @default.
• W1995356102 creator A5085745432 @default.
• W1995356102 date "2003-06-01" @default.
• W1995356102 modified "2023-10-10" @default.
• W1995356102 title "Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis" @default.
• W1995356102 cites W1966756689 @default.
• W1995356102 cites W1973248624 @default.
• W1995356102 cites W1974887827 @default.
• W1995356102 cites W1974903457 @default.
• W1995356102 cites W1977744551 @default.
• W1995356102 cites W1978655912 @default.
• W1995356102 cites W1979377048 @default.
• W1995356102 cites W1999359514 @default.
• W1995356102 cites W1999404885 @default.
• W1995356102 cites W2000500639 @default.
• W1995356102 cites W2018410379 @default.
• W1995356102 cites W2018697945 @default.
• W1995356102 cites W2020869366 @default.
• W1995356102 cites W2022917163 @default.
• W1995356102 cites W2026258433 @default.
• W1995356102 cites W2027454708 @default.
• W1995356102 cites W2030187620 @default.
• W1995356102 cites W2038535814 @default.
• W1995356102 cites W2041327354 @default.
• W1995356102 cites W2048468219 @default.
• W1995356102 cites W2065029052 @default.
• W1995356102 cites W2076276957 @default.
• W1995356102 cites W2080482139 @default.
• W1995356102 cites W2081833623 @default.
• W1995356102 cites W2091239293 @default.
• W1995356102 cites W2091452114 @default.
• W1995356102 cites W2098767548 @default.
• W1995356102 cites W2104908687 @default.
• W1995356102 cites W2115734700 @default.
• W1995356102 cites W2120676719 @default.
• W1995356102 cites W2127711040 @default.
• W1995356102 cites W2130393310 @default.
• W1995356102 cites W2131652664 @default.
• W1995356102 cites W2133744666 @default.
• W1995356102 cites W2141744584 @default.
• W1995356102 cites W2143510315 @default.
• W1995356102 cites W2165062595 @default.
• W1995356102 cites W2168698481 @default.
• W1995356102 cites W4292806894 @default.
• W1995356102 doi "https://doi.org/10.1002/art.11017" @default.
• W1995356102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12794835" @default.
• W1995356102 hasPublicationYear "2003" @default.
• W1995356102 type Work @default.
• W1995356102 sameAs 1995356102 @default.
• W1995356102 citedByCount "416" @default.
• W1995356102 countsByYear W19953561022012 @default.
• W1995356102 countsByYear W19953561022013 @default.
• W1995356102 countsByYear W19953561022014 @default.
• W1995356102 countsByYear W19953561022015 @default.
• W1995356102 countsByYear W19953561022016 @default.
• W1995356102 countsByYear W19953561022017 @default.
• W1995356102 countsByYear W19953561022018 @default.
• W1995356102 countsByYear W19953561022019 @default.
• W1995356102 countsByYear W19953561022020 @default.
• W1995356102 countsByYear W19953561022021 @default.
• W1995356102 countsByYear W19953561022022 @default.
• W1995356102 countsByYear W19953561022023 @default.
• W1995356102 crossrefType "journal-article" @default.
• W1995356102 hasAuthorship W1995356102A5010256118 @default.
• W1995356102 hasAuthorship W1995356102A5010659953 @default.
• W1995356102 hasAuthorship W1995356102A5011554462 @default.
• W1995356102 hasAuthorship W1995356102A5020029860 @default.
• W1995356102 hasAuthorship W1995356102A5035158215 @default.
• W1995356102 hasAuthorship W1995356102A5044290696 @default.
• W1995356102 hasAuthorship W1995356102A5069831361 @default.
• W1995356102 hasAuthorship W1995356102A5081920237 @default.
• W1995356102 hasAuthorship W1995356102A5085745432 @default.
• W1995356102 hasConcept C126322002 @default.
• W1995356102 hasConcept C142724271 @default.
• W1995356102 hasConcept C168563851 @default.
• W1995356102 hasConcept C17991360 @default.
• W1995356102 hasConcept C198451711 @default.
• W1995356102 hasConcept C204787440 @default.
• W1995356102 hasConcept C27081682 @default.
• W1995356102 hasConcept C2776260265 @default.
• W1995356102 hasConcept C2777226972 @default.
• W1995356102 hasConcept C2777402515 @default.
• W1995356102 hasConcept C2777453003 @default.
• W1995356102 hasConcept C2777575956 @default.
• W1995356102 hasConcept C2779650986 @default.
• W1995356102 hasConcept C61943457 @default.
• W1995356102 hasConcept C71924100 @default.
• W1995356102 hasConcept C90924648 @default.
• W1995356102 hasConceptScore W1995356102C126322002 @default.

• next